Strides partners with Kenox to expand nasal spray portfolio for US market
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Subscribe To Our Newsletter & Stay Updated